These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2909744)

  • 21. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    J Lipid Mediat; 1991; 3(2):225-37. PubMed ID: 1797154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of structural analogues of PAF-acether on platelet desensitization.
    Keraly CL; Coëffier E; Tencé M; Borrel MC; Benveniste J
    Br J Haematol; 1983 Mar; 53(3):513-21. PubMed ID: 6824590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
    Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
    J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
    Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (Pyridylcyanomethyl)piperazines as orally active PAF antagonists.
    Carceller E; Almansa C; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1992 Oct; 35(22):4118-34. PubMed ID: 1433215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical synthesis and physiological activity of sulfonium analogues of platelet activating factor.
    Kates M; Adams GA; Blank ML; Snyder F
    Lipids; 1991 Dec; 26(12):1095-101. PubMed ID: 1819693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs.
    Coëffier E; Borrel MC; Lefort J; Chignard M; Broquet C; Heymans F; Godfroid JJ; Vargaftig BB
    Eur J Pharmacol; 1986 Nov; 131(2-3):179-88. PubMed ID: 3816952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.
    Lamouri A; Heymans F; Tavet F; Dive G; Batt JP; Blavet N; Braquet P; Godfroid JJ
    J Med Chem; 1993 Apr; 36(8):990-1000. PubMed ID: 8478911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Schmidt B; Ostermann G
    Pharmazie; 1992 Mar; 47(3):172-4. PubMed ID: 1615020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].
    Kertscher HP; Ostermann G
    Pharmazie; 1991 Oct; 46(10):708-11. PubMed ID: 1803385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
    Kertscher HP; Ostermann G; Findeisen M; Limmer S; Gawrisch K
    Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
    J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of desensitization of vasodilatation induced by platelet-activating factor in hypertensive rats.
    Kamata K; Numazawa T; Kasuya Y
    Eur J Pharmacol; 1996 Apr; 301(1-3):121-8. PubMed ID: 8773455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP
    Pharmazie; 1997 Sep; 52(9):672-5. PubMed ID: 9411454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CV-3988 - a specific antagonist of platelet activating factor (PAF).
    Terashita Z; Tsushima S; Yoshioka Y; Nomura H; Inada Y; Nishikawa K
    Life Sci; 1983 Apr; 32(17):1975-82. PubMed ID: 6403793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological activities of bioisosteric O-carba-analogues of platelet activating factor (PAF).
    Nakamura N; Miyazaki H; Ohkawa N; Koike H; Sada T; Asai F; Kobayashi S
    Chem Pharm Bull (Tokyo); 1984 Jun; 32(6):2452-5. PubMed ID: 6488414
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.